Answers are grounded in this paper and cite their sources.
Investigations demonstrate anti-CSC activity in rhodium complexes, highlighting their potential in cancer treatment.
Investigations into the anticancer stem cell (CSC) properties of rhodium complexes are extremely rare. Here we report the synthesis, characterization, photophysical properties, and in vitro anti-CSC activity of a series of cyclometalated rhodium(III)-polypyridyl complexes 1-4. The 4,7-diphenyl-1,10-phenanthroline-bearing complex 4 exhibits activity against monolayer- and three-dimensionally cultured breast CSCs and osteosarcoma stem cells in the sub-micromolar to low micromolar range, outperforming the metallodrug cisplatin and the established anti-CSC agent salinomycin. Our results suggest that the reported rhodium(III) scaffold, containing cyclometalated 2,2′-(phenylmethylene)dipyridine, could be a useful synthon for the future development of anti-CSC rhodium complexes.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: